SMS Pharmaceuticals Q1 net profit rises 16% YoY to ₹20.9 crore
AI مارکیٹ کا خلاصہ
SMS Pharmaceuticals reported Q1FY27 consolidated net profit of ₹20.90 crore, up 16% YoY, while revenue was broadly flat, pointing to efficiency gains but limited demand expansion. The board also approved reappointing the Chairman & Managing Director and proposed an unsecured loan of up to ₹50 crore to its near wholly owned subsidiary, subject to shareholder approval. Overall implications are company specific with limited broader market spillover.
اثر کی سطح
● لو
متاثرہ اثاثے
NCCOGOLD2USD/USDT-0.15%
AI تجزیاتی سمجھ · NCCOGOLD2USD/USDTAI تجزیاتی سمجھ
● Neutral
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
SMS Pharmaceuticals posted Q1 FY2027 results for the quarter ended June 30, 2026, with consolidated net profit at ₹20.90 crore, up 16% year on year. Standalone net profit was ₹21.13 crore, also up 16%. Basic and diluted earnings per share were ₹2.23. The board approved the reappointment of Ramesh Babu Potluri as Chairman and Managing Director for five years from October 1, 2026, to September 30, 2031, subject to shareholder approval, and the company holds 99.99% of its subsidiary.
